Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: A case report

Experimental and Therapeutic Medicine

Volumn 4, Issue 4, 2012, Pages 661-664

  Jankun, Jerzy ^a,b,c  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Diabetes; Osmotic pump; Plasminogen activator inhibitor 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; HALF LIFE TIME; IN VIVO STUDY; KIDNEY; MOUSE; NONHUMAN; OSMOTIC PUMP; PROTEIN DEGRADATION;

EID: 84865389448     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.639     Document Type: Article

References (13)

1. Babin MC, Ricketts K, SkvorakJP, GazawayM, MitcheltreeLW and CasillasRP: Systemic administration of candidate antivesicants to protect against topically applied sulfur mustard in the mouse ear vesicant model (MEVM). J Appl Toxicol 20 (Suppl 1): S141-S144, 2000.
2. Buffelli M, BusettoG and CangianoA: The use of in vivo direct drug application to assess neural regulation of muscle properties. J Neurosci Methods 106: 113-120, 2001.
3. Knedla A, Riepl B, LefèvreS, et al: The therapeutic use of osmotic minipumps in the severe combined immunodeficiency (SCID) mouse model for rheumatoid arthritis. Ann Rheum Dis 68: 124-129, 2009.
4. Tejeda M, Gaal D, HullánL, et al: Continuous administration of the somatostatin structural derivative/TT-232/by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models. Anticancer Res 28: 2769-2774, 2008.
5. Swiercz R, Keck RW, Skrzypczak-Jankun E, SelmanSH and JankunJ: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 8: 463-470, 2001.
6. Huang Y, Border WA, LawrenceDA and NobleNA: Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. Am J Physiol Renal Physiol 297: F1045-F1054, 2009.
7. Huang Y, Border WA, Yu L, Zhang J, LawrenceDA and NobleNA: A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 19: 329-338, 2008.
8. Chorostowska-Wynimko J, SwierczR, Skrzypczak-JankunE, WojtowiczA, SelmanSH and JankunJ: A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2: 19-28, 2003.
9. Jankun J, Aleem AM, SpechtZ, et al: PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. Int J Mol Med 20: 11-20, 2007.
10. Hjortsø E, Jordening H, Jensen H, MunckO and QvistJ: The function of a continuous medication system in subatmospheric pressure environment. Scand J Clin Lab Invest 46: 293-295, 1986.
11. Kutz SM, Hordines J, McKeown-LongoPJ and HigginsPJ: TGF-β1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci 114: 3905-3914, 2001.
12. Samarakoon R, Higgins SP, Higgins CE and Higgins PJ: TGF-β1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol 44: 527-538, 2008.
13. Palmieri D, Lee JW, JulianoRL and ChurchFC: Plasminogen activator inhibitor-1 and-3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J Biol Chem 277: 40950-40957, 2002.